Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab in Progressive Multiple Sclerosis
NCT01077466Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Mar 2010
- Primary completion
- Jan 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of natalizumab in primary progressive multiple sclerosis (PPMS), secondary-progressive multiple sclerosis (SPMS), sponsored by Rigshospitalet. Started Mar 2010; status: completed.
02
Drugs
natalizumab
03
Conditions
primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT01077466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01077466.